摘要
2009年8月18日,307种药物进入基本药物目录,这是政府在推进基本药物制度坚实有力的一步。药品零售市场是一个极具潜力的市场,但由于有医保定点药店的存在,中国的药品零售市场是一个相对较弱的垄断市场。基本药物制度是政府在推进新医改过程中的激励性管制,有利于整合药品零售市场的资源,增加了药店经营的自主性,但是在价格和进入机制方面设立了障碍。在这种政府激励性管制的形势下,药店在经营过程中应该从多元化、更加注重药学服务和与社区医疗和上游的处方药供应商建立良好的关系等方面做出自己的战略选择。
On August 18, 2009 ,there were 307 kinds of drugs in the essential medicines catalog, which is a firm step of the government to promote the essential medicines system. The drug retail market is of great potency, but due to the existence of health insurance designated pharmacies, it is a weak monopoly market. The basic pharmaceuticals system is the incentive regulation in the process of new health system reform, which is good for integrating the resources of medicine retail market and increasing the autonomy of pharmacy business, but it provided obstacles in terms of price and access mechanism. Under the situation of incentive regulation by the government, the retail pharmacies should pay more attention to make their own strategy choice in terms of the diversification and pharmaceutical care, a good relationship with community health facilities, and with prescription drugs suppliers.
出处
《中国卫生政策研究》
2010年第1期54-57,共4页
Chinese Journal of Health Policy
关键词
基本药物制度
药品零售
激励性管制
战略选择
Essential medicines system
Retail of medicine
Incentive regulation
Strategy choice
